Clinical trial
Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage…
NCT00074087 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00074087 |
|---|---|
| Title | Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides |
| Official title | Phase II Clinical Trial With Caelyx Mono-Chemotherapy in Patients With Advanced Mycosis Fungoides Stage IIb, IVa and IVb With or Without Previous Chemotherapy |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | pegylated liposomal doxorubicin hydrochloride |
| Enrollment | 49 |
| Start date | Oct 1, 2003 |
| Primary completion | Jul 1, 2009 |
| Completion | Sep 1, 2010 |
| First posted | Dec 11, 2003 |
| Last update posted | Jul 9, 2018 |
| Countries | Austria, Germany, Israel, Italy, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: